Simvastatin modulates mouse embryonic stem cell-derived chondrogenesis in vitro

Toxicology in Vitro

Volumn 26, Issue 7, 2012, Pages 1170-1176

  Kramer, J ^a,b   Bartsch, M ^a   Krug, D ^a   Klinger, M ^a   Nitschke, M ^a   Rohwedel, J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Apoptosis; Cartilage; Chondrogenesis; ES cells; In vitro differentiation; Statin

Indexed keywords

BIOLOGICAL MARKER; CASPASE; COLLAGEN TYPE 2; SIMVASTATIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL DISRUPTION; CELL LOSS; CELL SURVIVAL; CHONDROGENESIS; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; EMBRYOID BODY; EMBRYONIC STEM CELL; EMBRYOTOXICITY; ENZYME ACTIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; PROCESS MODEL; PROTEIN EXPRESSION; UPREGULATION;

AGGRECANS; ANIMAL TESTING ALTERNATIVES; ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CHONDROCYTES; CHONDROGENESIS; COLLAGEN TYPE II; EMBRYOID BODIES; EMBRYONIC STEM CELLS; GENE EXPRESSION; HYPOLIPIDEMIC AGENTS; MICE; SIMVASTATIN; UP-REGULATION;

EID: 84866046088     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.06.013     Document Type: Article

References (52)

1. Balls M., Hellsten E. Statement of the scientific validity of the embryonic stem cell test (EST) - an in Vitro test for embryotoxicity. Altern. Lab. Anim. 2002, 30:265-268.
2. Barter M.J., Hui W., Lakey R.L., Catterall J.B., Cawston T.E., Young D.A. Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation. Ann. Rheum. Dis. 2010, 69:2189-2198.
3. Bremer S., Hartung T. The use of embryonic stem cells for regulatory developmental toxicity testing in vitro - the current status of test development. Curr. Pharm. Des. 2004, 10:2733-2747.
4. Buesen R., Genschow E., Slawik B., Visan A., Spielmann H., Luch A., Seiler A. Embryonic stem cell test remastered: comparison between the validated EST and the new molecular FACS-EST for assessing developmental toxicity in vitro. Toxicol. Sci. 2009, 108:389-400.
5. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 1999, 84:413-428.
6. Edison R.J., Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N. Engl. J. Med. 2004, 350:1579-1582.
7. Gauthaman K., Manasi N., Bongso A. Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br. J. Pharmacol. 2009, 157:962-973.
8. Genschow E., Spielmann H., Scholz G., Pohl I., Seiler A., Clemann N., Bremer S., Becker K. Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern. Lab. Anim. 2004, 32:209-244.
9. Haller R., Schwanbeck R., Martini S., Bernoth K., Kramer J., Just U., Rohwedel J. Notch1 signaling regulates chondrogenic lineage determination through Sox9 activation. Cell Death Differ. 2011, 19:461-469.
10. Hargus G., Kist R., Kramer J., Gerstel D., Neitz A., Scherer G., Rohwedel J. Loss of Sox9 function results in defective chondrocyte differentiation of mouse embryonic stem cells in vitro. Int. J. Dev. Biol. 2008, 52:323-332.
11. Hatano H., Maruo A., Bolander M.E., Sarkar G. Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J. Orthop. Sci. 2003, 8:842-848.
12. Hegert C., Kramer J., Hargus G., Muller J., Guan K., Wobus A.M., Muller P.K., Rohwedel J. Differentiation plasticity of chondrocytes derived from mouse embryonic stem cells. J. Cell Sci. 2002, 115:4617-4628.
13. Heuer J., Bremer S., Pohl I., Spielmann H. Development of an in vitro embryotoxicity test using murine embryonic stem cell cultures. Toxicol. In Vitro 1993, 7:551-556.
14. Kolossov E., Fleischmann B.K., Liu Q., Bloch W., Viatchenko-Karpinski S., Manzke O., Ji G.J., Bohlen H., Addicks K., Hescheler J. Functional characteristics of ES cell-derived cardiac precursor cells identified by tissue-specific expression of the green fluorescent protein. J. Cell Biol. 1998, 143:2045-2056.
15. Kramer J., Hegert C., Guan K., Wobus A.M., Muller P.K., Rohwedel J. Embryonic stem cell-derived chondrogenic differentiation in vitro: activation by BMP-2 and BMP-4. Mech. Dev. 2000, 92:193-205.
16. Kramer J., Hegert C., Hargus G., Rohwedel J. Mouse ES cell lines show a variable degree of chondrogenic differentiation in vitro. Cell Biol. Int. 2005, 29:139-146.
17. Laschinski G., Vogel R., Spielmann H. Cytotoxicity test using blastocyst-derived euploid embryonal stem cells: a new approach to in vitro teratogenesis screening. Reprod. Toxicol. 1991, 5:57-64.
18. Lazzerini P.E., Capecchi P.L., Nerucci F., Fioravanti A., Chellini F., Piccini M., Bisogno S., Marcolongo R., Laghi Pasini F. Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann. Rheum. Dis. 2004, 63:867-869.
19. Lazzerini P.E., Capecchi P.L., Selvi E., Lorenzini S., Bisogno S., Baldari C.T., Galeazzi M., Laghi-Pasini F. Statins and the joint: multiple targets for a global protection?. Semin. Arthritis Rheum. 2010, 40:430-446.
20. Lee M.H., Cho Y.S., Han Y.M. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Stem Cells 2007, 25:1654-1663.
21. Maltsev V.A., Rohwedel J., Hescheler J., Wobus A.M. Embryonic stem cells differentiate in vitro into cardiomyocytes representing sinusnodal, atrial and ventricular cell types. Mech. Dev. 1993, 44:41-50.
22. Manson J.M., Freyssinges C., Ducrocq M.B., Stephenson W.P. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod. Toxicol. 1996, 10:439-446.
23. Marx-Stoelting P., Adriaens E., Ahr H.J., Bremer S., Garthoff B., Gelbke H.P., Piersma A., Pellizzer C., Reuter U., Rogiers V., Schenk B., Schwengberg S., Seiler A., Spielmann H., Steemans M., Stedman D.B., Vanparys P., Vericat J.A., Verwei M., van der Water F., Weimer M., Schwarz M. A review of the implementation of the embryonic stem cell test (EST). The report and recommendations of an ECVAM/ReProTect Workshop. Altern. Lab. Anim. 2009, 37:313-328.
24. Metzger J.M., Lin W.I., Samuelson L.C. Vital staining of cardiac myocytes during embryonic stem cell cardiogenesis in vitro. Circ. Res. 1996, 78:547-552.
25. Nwokoro N.A., Wassif C.A., Porter F.D. Genetic disorders of cholesterol biosynthesis in mice and humans. Mol. Genet. Metab. 2001, 74:105-119.
26. Paquette J.A., Kumpf S.W., Streck R.D., Thomson J.J., Chapin R.E., Stedman D.B. Assessment of the Embryonic Stem Cell Test and application and use in the pharmaceutical industry. Birth Defects Res. B Dev. Reprod. Toxicol. 2008, 83:104-111.
27. Peters A.K., Steemans M., Hansen E., Mesens N., Verheyen G.R., Vanparys P. Evaluation of the embryotoxic potency of compounds in a newly revised high throughput embryonic stem cell test. Toxicol. Sci. 2008, 105:342-350.
28. Petersen E.E., Mitchell A.A., Carey J.C., Werler M.M., Louik C., Rasmussen S.A. Maternal exposure to statins and risk for birth defects: a case-series approach. Am. J. Med. Genet. A 2008, 146A:2701-2705.
29. Phillips B.W., Belmonte N., Vernochet C., Ailhaud G., Dani C. Compactin enhances osteogenesis in murine embryonic stem cells. Biochem. Biophys. Res. Commun. 2001, 284:478-484.
30. Pollack P.S., Shields K.E., Burnett D.M., Osborne M.J., Cunningham M.L., Stepanavage M.E. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res. A Clin. Mol. Teratol. 2005, 73:888-896.
31. Rohwedel J., Guan K., Hegert C., Wobus A.M. Embryonic stem cells as an in vitro model for mutagenicity, cytotoxicity and embryotoxicity studies: present state and future prospects. Toxicol. In Vitro 2001, 15:741-753.
32. Rohwedel J., Guan K., Wobus A.M. Induction of cellular differentiation by retinoic acid in vitro. Cells Tissues Organs 1999, 165:190-202.
33. Roux C., Wolf C., Mulliez N., Gaoua W., Cormier V., Chevy F., Citadelle D. Role of cholesterol in embryonic development. Am. J. Clin. Nutr. 2000, 71:1270S-1279S.
34. Sauer H., Gunther J., Hescheler J., Wartenberg M. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am. J. Pathol. 2000, 156:151-158.
35. Schmidt M.M., Guan K., Wobus A.M. Lithium influences differentiation and tissue-specific gene expression of mouse embryonic stem (ES) cells in vitro. Int. J. Dev. Biol. 2001, 45:421-429.
36. Seiler A., Visan A., Buesen R., Genschow E., Spielmann H. Improvement of an in vitro stem cell assay for developmental toxicity: the use of molecular endpoints in the embryonic stem cell test. Reprod. Toxicol. 2004, 18:231-240.
37. Seiler A.E., Buesen R., Visan A., Spielmann H. Use of murine embryonic stem cells in embryotoxicity assays: the embryonic stem cell test. Methods Mol. Biol. 2006, 329:371-395.
38. Seiler A.E., Spielmann H. The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat. Protoc. 2011, 6:961-978.
39. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J. Intern. Med. 2006, 260:305-319.
40. Spielmann H. Reproduction and development. Environ. Health Perspect. 1998, 106(Suppl. 2):571-576.
41. Spielmann H. The way forward in reproductive/developmental toxicity testing. Altern. Lab. Anim. 2009, 37:641-656.
42. Spielmann H., Seiler A., Bremer S., Hareng L., Hartung T., Ahr H., Faustman E., Haas U., Moffat G.J., Nau H., Vanparys P., Piersma A., Sintes J.R., Stuart J. The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). Altern. Lab. Anim. 2006, 34:527-538.
43. Taguchi N., Rubin E.T., Hosokawa A., Choi J., Ying A.Y., Moretti M.E., Koren G., Ito S. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod. Toxicol. 2008, 26:175-177.
44. Wobus A.M., Boheler K.R. Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol. Rev. 2005, 85:635-678.
45. Wobus A.M., Holzhausen H., Jakel P., Schoneich J. Characterization of a pluripotent stem cell line derived from a mouse embryo. Exp. Cell Res. 1984, 152:212-219.
46. Wobus A.M., Kaomei G., Shan J., Wellner M.C., Rohwedel J., Ji G., Fleischmann B., Katus H.A., Hescheler J., Franz W.M. Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. J. Mol. Cell Cardiol. 1997, 29:1525-1539.
47. Wobus A.M., Loser P. Present state and future perspectives of using pluripotent stem cells in toxicology research. Arch. Toxicol. 2011, 85:79-117.
48. Wobus A.M., Rohwedel J., Maltsev V.A., Hescheler J. In vitro differentiation of embryonic stem cells into cardiomyocytes or skeletal muscle cells is specifically modulated by retinoic acid. Roux's Arch. Dev. Biol. 1994, 204:36-45.
49. 2+ channel blockers. Differentiation 1991, 48:173-182.
50. Wu S., De Luca F. Role of cholesterol in the regulation of growth plate chondrogenesis and longitudinal bone growth. J. Biol. Chem. 2004, 279:4642-4647.
51. Zhang H., Lin C.Y. Simvastatin stimulates chondrogenic phenotype of intervertebral disc cells partially through BMP-2 pathway. Spine (Phila Pa 1976) 2008, 33:E525-E531.
52. Zur Nieden N.I., Kempka G., Ahr H.J. Molecular multiple endpoint embryonic stem cell test - a possible approach to test for the teratogenic potential of compounds. Toxicol. Appl. Pharmacol. 2004, 194:257-269.